Cancer Research UK says it hopes its partnership with a global venture capital firm will speed up the discovery of drugs.
The charity is injecting at least $25 million (£20m) into SV Heath Investors’ planned $250m biotech venture capital fund, it announced on 2 July. The London-headquartered firm plans to direct 60 per cent of the fund into oncology-related companies.
Cancer Research UK and SV have a long history of collaboration, with the charity supporting the firm to establish several cancer-based pharmaceutical companies since 1998.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.